US2002094340A1PendingUtilityA1

Chlamydia antigens and corresponding dna thereof

34
Priority: Dec 1, 1998Filed: Dec 1, 1999Published: Jul 18, 2002
Est. expiryDec 1, 2018(expired)· nominal 20-yr term from priority
Inventors:Andrew D. MurdinRaymond P. OomenJoe WangPamela Dunn
C07K 14/295A61P 31/04Y10S530/814A61K 2039/505Y10S530/82A61K 2039/53A61K 39/118A61K 38/00C07K 2319/01E02D 3/02C07K 2319/02Y10S530/811A61K 39/00
34
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.

Claims

exact text as granted — not AI-modified
1 . A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any of: 
 (a) SEQ ID Nos: 3 and 4;    (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and    (c) a polypeptide of (a) or (b) which has been modified to improve its immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).    
     
     
         2 . A nucleic acid molecule comprising a nucleic acid sequence selected from any of: 
 (a) SEQ ID Nos: 1 and 2;    (b) a sequence which encodes a polypeptide encoded by SEQ ID No: 1 or 2;    (c) a sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (a) and (b); and    (d) a sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to the polypeptides encoded by SEQ ID No: 1 or 2.    
     
     
         3 . A nucleic acid molecule comprising a nucleic acid sequence which is anti-sense to the nucleic acid molecule of  claim 1  or  2 .  
     
     
         4 . A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule according to  claim 1  and an additional polypeptide.  
     
     
         5 . The nucleic acid molecule of  claim 4  wherein the additional polypeptide is a heterologous signal peptide.  
     
     
         6 . The nucleic acid molecule of  claim 4  wherein the additional polypeptide has adjuvant activity.  
     
     
         7 . A nucleic acid molecule according to any one of  claims 1  to  6 , operatively linked to one or more expression control sequences.  
     
     
         8 . A vaccine comprising at least one first nucleic acid according to any one of claims  1 ,  2 , and  4  to  7  and a vaccine vector wherein each first nucleic acid is expressed as a polypeptide, the vaccine optionally comprising a second nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by said first nucleic acid.  
     
     
         9 . The vaccine of  claim 8  wherein the second nucleic acid encodes an additional Chlamydia polypeptide.  
     
     
         10 . A pharmaceutical composition comprising a nucleic acid according to any one of  claims 1  to  7  and a pharmaceutically acceptable carrier.  
     
     
         11 . A pharmaceutical composition comprising a vaccine according to  claim 8  or  9  and a pharmaceutically acceptable carrier.  
     
     
         12 . A unicellular host transformed with the nucleic acid molecule of  claim 7 .  
     
     
         13 . A nucleic acid probe of 5 to 100 nucleotides which hybridizes under stringent conditions to the nucleic acid molecule of SEQ ID No: 1 or 2, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.  
     
     
         14 . A primer of 10 to 40 nucleotides which hybridizes under stringent conditions to the nucleic acid molecules of SEQ ID No: 1 or 2, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.  
     
     
         15 . A polypeptide encoded by a nucleic acid sequence according to any one of claims  1 ,  2  and  4  to  7 .  
     
     
         16 . A polypeptide comprising an amino acid sequence selected from any of: 
 (a) SEQ ID Nos: 3 and 4;    (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and    (c) a polypeptide of (a) or (b) which has been modified to improve its immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).    
     
     
         17 . A fusion polypeptide comprising a polypeptide of  claim 15  or  16  and an additional polypeptide.  
     
     
         18 . The fusion polypeptide of  claim 17  wherein the additional polypeptide is a heterologous signal peptide.  
     
     
         19 . The fusion protein of  claim 17  wherein the additional polypeptide has adjuvant activity.  
     
     
         20 . A method for producing a polypeptide of  claim 15  or  16 , comprising the step of culturing a unicellular host according to  claim 12 .  
     
     
         21 . An antibody against the polypeptide of any one of  claims 15  to  19 .  
     
     
         22 . A vaccine comprising at least one first polypeptide according to any one of  claims 15  to  19  and a pharmaceutically acceptable carrier, optionally comprising a second polypeptide which enhances the immune response to the first polypeptide.  
     
     
         23 . The vaccine of  claim 22  wherein the second polypeptide comprises an additional Chlamydia polypeptide.  
     
     
         24 . A pharmaceutical composition comprising a polypeptide according to any one of  claims 15  to  19  and a pharmaceutically acceptable carrier.  
     
     
         25 . A pharmaceutical composition comprising a vaccine according to  claim 22  or  23  and a pharmaceutically acceptable carrier.  
     
     
         26 . A pharmaceutical composition comprising an antibody according to  claim 21  and a pharmaceutically acceptable carrier.  
     
     
         27 . A method for preventing or treating Chlamydia infection using: 
 (a) the nucleic acid of any one of  claims 1  to  7 ;    (b) the vaccine of any one of claims  8 ,  9 ,  22  and  23 ;    (c) the pharmaceutical composition of any one of claims  10 ,  11 ,  24  to  26 ;    (d) the polypeptide of any one of  claims 15  to  19 ; or    (e) the antibody of  claim 21 .    
     
     
         28 . A method of detecting Chlamydia infection comprising the step of assaying a body fluid of a mammal to be tested, with a component selected from any one of: 
 (a) the nucleic acid of any one of  claims 1  to  7 ;    (b) the polypeptide of any one of  claims 15  to  19 ; and    (c) the antibody of  claim 21 .    
     
     
         29 . A diagnostic kit comprising instructions for use and a component selected from any one of: 
 (a) the nucleic acid of any one of  claims 1  to  7 ;    (b) the polypeptide of any one of  claims 15  to  19 ; and    (c) the antibody of  claim 21 .    
     
     
         30 . A method for identifying a polypeptide of  claims 15  to  19  which induces an immune response effective to prevent or lessen the severity of Chlamydia infection in a mammal previously immunized with polypeptide, comprising the steps of: 
 (a) immunizing a mouse with the polypeptide; and  
 (b) inoculating the immunized mouse with Chlamydia;  
 wherein the polypeptide which prevents or lessens the severity of Chlamydia infection in the immunized mouse compared to a non-immunized control mouse is identified.  
 
     
     
         31 . Expression plasmid pCAI640.

Join the waitlist — get patent alerts

Track US2002094340A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.